What is stanozolol used for?

Stanozolol has historically been studied in medical contexts for conditions such as hereditary angioedema and for anabolic support physiology.

Is stanozolol the same as Winstrol?

Yes, Winstrol is the commonly known brand name for the compound Stanozolol.

Does stanozolol help build muscle?

Stanozolol is associated with anabolic activity that may support protein synthesis and lean muscle development.

How long does stanozolol stay active?

The duration of activity depends on the formulation, but injectable stanozolol may remain active in the body for several days.

What are the side effects of stanozolol?

Possible side effects include hormonal imbalance, acne, cholesterol changes, and other androgen related effects.

Stanozolol Injectable (CAS 10418-03-8)

Name: Stanozolol
Brand: Nova Techsciences
SKU: roxonova

Quick Facts

Form

Injectable solution

Strength

Stanozolol 50 mg/ml

Pack Size

10 ml multidose vial

Route

Intramuscular (IM) injection

Indication

ROXONOVA Stanozolol Injectable (CAS 10418-03-8)What is Stanozolol (CAS 10418-03-8)?Mechanism of ActionProtein synthesis and muscle tissue developmentNitrogen retention within muscle cellsIncreased strength and endurance environments

ROXONOVA Stanozolol Injectable (CAS 10418-03-8)

ROXONOVA Injectable by NovaTech Sciences contains pharmaceutical-grade Stanozolol (CAS 10418-03-8), a synthetic anabolic androgenic compound widely recognized for its association with strength development, lean muscle environments, and performance physiology. The compound is globally identified through CAS 10418-03-8, ensuring chemical authenticity, pharmaceutical traceability, and standardized compound identification across international pharmaceutical markets.

NovaTech Sciences manufactures Stanozolol CAS 10418-03-8 using advanced pharmaceutical technologies designed to maintain compound purity, sterile injectable formulation quality, and reliable global distribution.

What is Stanozolol (CAS 10418-03-8)?

Stanozolol, registered under CAS 10418-03-8, is a synthetic derivative of dihydrotestosterone (DHT). It is widely recognized for its anabolic properties and has historically been studied in medical and performance-related contexts.

The CAS registry number 10418-03-8 serves as the globally recognized chemical identifier for Stanozolol. This identifier ensures compound verification, regulatory documentation, and pharmaceutical transparency across manufacturing and distribution systems.

Stanozolol gained prominence in medical research for applications involving hereditary angioedema and conditions related to muscle preservation.

Mechanism of Action

Stanozolol CAS 10418-03-8 works by interacting with androgen receptors located throughout the body. Once administered, the compound influences several biological processes associated with anabolic signaling and metabolic activity.

Activation of androgen receptors contributes to

Protein synthesis and muscle tissue development

Nitrogen retention within muscle cells

Increased strength and endurance environments

Enhanced red blood cell production

Lean muscle preservation and metabolic efficiency

Because of its unique chemical structure, Stanozolol CAS 10418-03-8 is often associated with lean muscle development rather than water retention environments.

Key Features of Stanozolol CAS 10418-03-8

ROXONOVA injectable provides pharmaceutical-grade Stanozolol (CAS 10418-03-8) with several defining characteristics

Verified CAS 10418-03-8 compound identity

Association with lean muscle development environments

Support for strength and performance physiology

Recognized anabolic compound in research contexts

Pharmaceutical-grade sterile injectable manufacturing

Each production batch of Stanozolol CAS 10418-03-8 undergoes strict laboratory testing to verify compound identity, purity levels, and sterile pharmaceutical quality.

Pharmaceutical Manufacturing & Global Supply

NovaTech Sciences operates as a trusted manufacturer, supplier, and exporter of pharmaceutical-grade anabolic compounds for global healthcare markets. By specifying CAS 10418-03-8, ROXONOVA injectable maintains chemical authenticity and regulatory compliance.

Manufacturing protocols include

Raw material authentication

CAS-verified compound validation

Controlled sterile injectable production environments

Batch consistency and sterility testing

Export-compliant pharmaceutical packaging

These strict quality assurance systems ensure Stanozolol injectable formulations meet pharmaceutical distribution standards required by international partners.

Why Choose ROXONOVA by NovaTech Sciences?

NovaTech Sciences focuses on pharmaceutical precision, regulatory compliance, and consistent formulation quality. ROXONOVA containing Stanozolol CAS 10418-03-8 is manufactured using advanced pharmaceutical processes designed to maintain stable formulation performance.

Key advantages include

Pharmaceutical-grade sterile injectable standards

Verified CAS compound identification

Trusted global manufacturing reputation

Consistent batch-to-batch product quality

Reliable international export supply capability

Conclusion

For pharmaceutical distributors and healthcare suppliers seeking a dependable source of Stanozolol (CAS 10418-03-8), ROXONOVA Injectable by NovaTech Sciences offers verified compound identity, pharmaceutical manufacturing excellence, and reliable global supply. Supported by strict quality assurance protocols, Stanozolol CAS 10418-03-8 remains a recognized anabolic compound associated with lean muscle environments, strength development, and performance physiology.

Safety Information

Precautions

Use only under physician supervision.
Regular liver function and lipid profile monitoring is strongly advised.
Avoid alcohol consumption during use to reduce liver toxicity.
Monitor for joint discomfort as Stanozolol may cause joint dryness.
Long-term unsupervised use may suppress natural testosterone production.

Contraindications

Contraindicated in patients with liver disease, liver tumors, or severe hepatic dysfunction.
Not recommended for pregnant or breastfeeding women.
Avoid use in patients with prostate cancer or male breast cancer.
Not suitable for individuals with severe cardiovascular disease or uncontrolled cholesterol disorders.
Contraindicated in individuals with hypersensitivity to Stanozolol or formulation ingredients.

Indication

ROXONOVA Stanozolol Injectable (CAS 10418-03-8)